PTC Therapeutics Prices $500M 0% Convertible Notes at 40% Premium to Refinance 2026 Debt
PTCT sits 78% above its 52-week low of $43.175 on elevated volume (2.8× avg).
Summary
PTC Therapeutics has priced a $500 million offering of 0% Convertible Senior Notes due 2031, with an option for an additional $50 million. This follows the company's announcement yesterday of a proposed $500 million convertible note offering. The notes feature a 0% interest rate and an initial conversion price of $107.48, a 40% premium over the current stock price. This favorable refinancing transaction will be used to repurchase or repay the company's higher-interest 2026 convertible notes, reducing future interest expenses and pushing out debt maturity.
At the time of this announcement, PTCT was trading at $76.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $43.18 to $87.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.